← Browse by Condition

Medical Condition

alzheimer s disease

Total Trials

18

Recruiting Now

18

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for alzheimer s disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — alzheimer s disease Clinical Trials

How many clinical trials are currently recruiting for alzheimer s disease?

ClinicalMetric currently tracks 18 actively recruiting clinical trials for alzheimer s disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 18. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for alzheimer s disease?

alzheimer s disease research spans Phase 1 (6 trials), Phase 2 (3 trials), Phase 3 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a alzheimer s disease clinical trial?

Eligibility criteria for alzheimer s disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

6

Phase 2

3

Phase 3

1

Phase 4

1

Top Sponsors

National Institute of Mental Health (NIMH) 2 trials

University of Cambridge 1 trial

Oregon Health and Science University 1 trial

University of Pennsylvania 1 trial

Tianjin Medical University 1 trial

Recruiting Clinical Trials

The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions

University of Cambridge

NCT05591027 Phase 1

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Oregon Health and Science Univ...

Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

University of Pennsylvania

[18F]NIDF PET Imaging in Tau-related Diseases

Tianjin Medical University

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

Russian Federation of Anesthes...

Ultrasonic Debris Clearance to Promote Brain Resilience

Stanford University

NCT07279740 Phase 2

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

Sunnybrook Health Sciences Cen...

NCT05462106 Phase 1, Phase 2

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

United States, Spain...

NCT04396873 Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

National Institute of Mental H...

Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons

Kessler Foundation

NCT07780383 Phase 1

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

Bristol-Myers Squibb

NCT07599670 Phase 1, Phase 2

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

United States, China

NCT07169630 Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

National Institute of Mental H...

NCT07752784 Phase 3

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

JYAMS PET Research & Developme...

Lombard Cohort of Brain Health Services

University of Milano Bicocca

Retinal Imaging in Neurodegenerative Disease

Duke University

NCT07604896 Phase 4

Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

First Affiliated Hospital of W...

Choose Myself (Before) Losing Myself

The Cleveland Clinic

Related Conditions

mild cognitive impairment (6) parkinson s disease (4) dementia (3) alzheimer dementia ad (3) dementia diagnosis (2) alzheimer dementia (2) alzheimer disease (2) traumatic brain injury (2) parkinson disease disorder (1) parkinson (1) parkinson disease (1) rem behavior disorder (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology